RECOVER-LV
Trial Sponsored by:
Trial Approval: Pending
Research Profile:
Dr Kieran F. Docherty Ross Campbell
Trial: clinicaltrials.gov
Trial Summary
RECOVER-LV: The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Patients with left ventricular (LV) systolic dysfunction after myocardial infarction (MI) are at a high risk of developing heart failure. The addition of neprilysin inhibition to renin-angiotensin-aldosterone-system (RAAS) inhibition may result in greater attenuation of adverse LV remodelling as a result of increased levels of substrates for neprilysin with vasodilatory, antihypertrophic, antifibrotic and sympatholytic effects.
This prospective, multi-centre, randomised, double-blind, active-comparator trial compared the addition of neprilysin inhibition to RAAS blockade (using sacubitril/valsartan) to RAAS blockade alone (using valsartan) in patients ≥3 months after MI with a LV ejection fraction ≤40%.
Investigators
Chief Investigator
Dep Chief Investigator
Co-Investigators
Trial Project Manager
Patient Recruitment
Recruitment status: Pending